|Mr. Donald J. McCaffrey||Co-Founder, Chairman, Pres, CEO & Sec.||505.2k||N/A||N/A|
|Mr. Aaron Bradley Cann C.A., CPA, CA, CPA, CBV||Chief Financial Officer||281.8k||N/A||N/A|
|Mr. Kenneth Eugene Lebioda BA||Sr. VP of Bus. & Corp. Devel.||264.6k||N/A||N/A|
|Dr. Michael Sweeney||Sr. VP of Clinical Devel.||525.29k||N/A||1961|
|Dr. Ewelina Kulikowski||Sr. VP of R&D||250k||N/A||N/A|
|Dr. Norman C.W. Wong B.Sc., FRCPC, M.Sc., B.Sc (Hon), M.Sc, M.D., FRCP(||Co-Founder, Chief Scientific Officer & Chairman of the Scientific Advisory Board||N/A||N/A||N/A|
|Mr. Paul Moon||VP of Investor Relations & Communications||N/A||N/A||N/A|
|Sarah Zapotichny||Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Dr. Jan O. Johansson||Sr. VP of Medical Affairs||N/A||N/A||N/A|
Resverlogix Corp. operates as a late-stage clinical biotechnology company. The company is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trials for patients with cardiovascular, chronic kidney, end-stage renal, neurodegenerative, fabry, peripheral artery, and other orphan diseases, as well as diabetes mellitus. Resverlogix Corp. is headquartered in Calgary, Canada.
Resverlogix Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.